Relay Therapeutics (RLAY) stock price is $18.45, up 7.96% on the day, as of Oct 20, 2026. It has a market cap of $3.76Bn, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap3.76 Bn
P/E-13.14
P/S363.07
Div. Yield0.00
Revenue Growth (1y) (Qtr)-48.30
Add ratio to table…
About
Relay Therapeutics Inc is a clinical stage small molecule precision medicine company developing potentially life changing therapies for patients living with cancer and genetic disease. The company leverages its Dynamo platform which integrates computational and experimental approaches to study protein motion and apply insights to drug design a method it terms Motion Based Drug Design. This approach targets proteins that have been difficult to drug with conventional methods…
Relay Therapeutics Inc is a clinical stage small molecule precision medicine company developing potentially life changing therapies for patients living with cancer and genetic disease. The company leverages its Dynamo platform which integrates computational and experimental approaches to study protein motion and apply insights to drug design a method it terms Motion Based Drug Design. This approach targets proteins that have been difficult to drug with conventional methods focusing on genetically validated targets in oncology and genetic disease. Its pipeline includes the lead candidate zovegalisib, an allosteric pan mutant isoform selective PI3K inhibitor being evaluated in breast cancer, and vascular anomalies, as well as programs such as an NRAS selective inhibitor for solid tumors, a non inhibitory chaperone for Fabry disease, and early stage discovery efforts across both therapeutic areas.
Revenue is currently generated through collaboration and licensing agreements rather than product sales as the company has no approved therapies on the market. It has received an upfront payment of $75 million, and $45 million in milestone payments from Genentech under their collaboration agreement. Additionally it has entered into an exclusive global licensing agreement with Elevar Therapeutics for lirafugratinib, and a clinical trial collaboration with Pfizer to evaluate combination regimens in breast cancer. These arrangements provide upfront payments, milestone payments, and potential royalties forming the company’s revenue stream while it advances its pipeline.
Relay Therapeutics occupies a niche within the biotechnology industry by focusing on structure based drug design that incorporates protein dynamics distinguishing it from competitors that rely on static structural methods. Key competitors in its PI3Kα focused programs include Novartis with alpelisib, AstraZeneca with capivasertib, and Roche Genetech with inavolisib while in broader precision oncology it faces competition from other biotech firms pursuing similar motion based or structure driven approaches. The company’s competitive advantages stem from its proprietary Dynamo platform which enables the discovery of allosteric selective inhibitors and provides a differentiated pipeline targeting historically undruggable proteins.
The company’s collaborators and customers include major pharmaceutical firms such as Genentech, Pfizer, and Elevar Therapeutics as well as research organizations like D. E. Shaw Research. These partners engage in licensing, co development, and clinical trial collaborations to advance the drug candidates toward potential commercialization.
Sector:HealthcareSector rationaleRelay Therapeutics is a clinical-stage biotechnology company developing small molecule therapies for cancer and genetic diseases, such as zovegalisib. Its revenue is derived from collaboration and licensing agreements with pharmaceutical firms like Genentech and Pfizer to advance these medical drug candidates.Industry:BiotechnologyBiotechnologyPrimaryRelay Therapeutics is a clinical-stage biotechnology company that uses its Dynamo platform to develop small molecule therapies for cancer and genetic diseases. Its revenue is currently derived from collaboration and milestone payments from partners like Genentech and Pfizer, which is characteristic of the H-02 classification.Classified using BQ-MICSCIK: 0001812364
Bull & bear
Investment Thesis
▲ Bull case
Relay Therapeutics (RLAY) demonstrated meaningful clinical progress in its mid-stage trial for the experimental treatment targeting rare vascular disorders, as evidenced by tumor shrinkage and symptom improvement in patients, which directly validates the company's core platform strategy of using computational biology to identify and develop precision oncology and rare disease therapies. The positive data readout not only confirms biological activity in a difficult-to-treat patient population but also suggests potential for regulatory acceleration pathways given the rarity and severity of the condition, reducing near-term clinical and regulatory risk. This outcome could serve as a foundational proof point for expanding the pipeline into additional vascular or rare disease indications where high unmet need and limited competition exist, thereby de-risking future R&D investments. The market's initial reaction of over 13% premarket share price increase reflects recognition of this validation, but may still underappreciate the long-term optionality of applying the same AI-driven drug discovery engine to other genetically defined rare diseases beyond vascular disorders.
Despite the lack of a recent earnings call transcript, the strength of the vascular disorder trial results implies that Relay Therapeutics (RLAY) is advancing beyond its primary oncology focus, signaling a strategic diversification that could reduce reliance on any single therapeutic area and broaden its revenue potential over time. The ability to generate clinically meaningful data in a rare disease setting—where patient recruitment is typically challenging and endpoints are harder to achieve—highlights the robustness of its Dynamo platform in identifying actionable targets across diverse disease architectures. This success may attract partnership interest from larger pharmaceutical companies seeking innovative rare disease assets, potentially unlocking non-dilutive funding or milestone-driven collaborations that remain underappreciated in the current valuation. Furthermore, the rarity of the indication increases the likelihood of orphan drug designation, which confers tax credits, fee waivers, and seven years of U.S. market exclusivity post-approval, significantly enhancing the long-term economic profile of any future commercialized product.
Relay Therapeutics (RLAY) demonstrated meaningful clinical progress in its mid-stage trial for the experimental treatment targeting rare vascular disorders, as evidenced by tumor shrinkage and symptom improvement in patients, which directly validates the company's core platform strategy of using computational biology to identify and develop precision oncology and rare disease therapies. The positive data readout not only confirms biological activity in a difficult-to-treat patient population but also suggests potential for regulatory acceleration pathways given the rarity and severity of the condition, reducing near-term clinical and regulatory risk. This outcome could serve as a foundational proof point for expanding the pipeline into additional vascular or rare disease indications where high unmet need and limited competition exist, thereby de-risking future R&D investments. The market's initial reaction of over 13% premarket share price increase reflects recognition of this validation, but may still underappreciate the long-term optionality of applying the same AI-driven drug discovery engine to other genetically defined rare diseases beyond vascular disorders.
Despite the lack of a recent earnings call transcript, the strength of the vascular disorder trial results implies that Relay Therapeutics (RLAY) is advancing beyond its primary oncology focus, signaling a strategic diversification that could reduce reliance on any single therapeutic area and broaden its revenue potential over time. The ability to generate clinically meaningful data in a rare disease setting—where patient recruitment is typically challenging and endpoints are harder to achieve—highlights the robustness of its Dynamo platform in identifying actionable targets across diverse disease architectures. This success may attract partnership interest from larger pharmaceutical companies seeking innovative rare disease assets, potentially unlocking non-dilutive funding or milestone-driven collaborations that remain underappreciated in the current valuation. Furthermore, the rarity of the indication increases the likelihood of orphan drug designation, which confers tax credits, fee waivers, and seven years of U.S. market exclusivity post-approval, significantly enhancing the long-term economic profile of any future commercialized product.
Relay Therapeutics (RLAY) remains heavily dependent on the success of its oncology pipeline, particularly its lead programs targeting well-established drivers like SHP2 and FGFR2, yet the recent news exclusively highlights progress in a rare vascular disorder indication—raising questions about whether the company is shifting focus away from its core cancer franchises due to disappointing or stalled oncology data that were not disclosed in the update. The absence of any mention of oncology trial progress in the news release, combined with no recent earnings call to provide context, suggests potential evasion or lack of material progress in higher-value cancer indications, which could imply that the vascular data, while scientifically encouraging, may not be representative of the company's broader R&D productivity. Investors should scrutinize whether resources are being diverted from higher-potential but riskier oncology bets to lower-complexity rare disease projects as a means of generating near-term news flow.
While the vascular disorder trial showed tumor shrinkage and symptom improvement, the news release provided no clarity on key differentiators such as durability of response, comparative efficacy against existing off-label therapies, or safety profile in a chronically ill patient population—critical factors that determine whether this asset can achieve meaningful commercial traction or merely serve as a scientific curiosity. Rare vascular disorders often have limited patient populations (potentially fewer than a few thousand eligible patients globally), which constrains peak sales potential even under optimistic pricing assumptions, and may not justify the high R&D spend associated with Relay’s platform-dependent drug discovery model without clear paths to expansion into larger indications. Furthermore, the company’s reliance on its proprietary Dynamo platform introduces execution risk; if the vascular success is viewed as an isolated incident rather than a repeatable outcome, skepticism may grow regarding the platform’s ability to consistently deliver clinically differentiated candidates across therapeutic areas.
Relay Therapeutics (RLAY) remains heavily dependent on the success of its oncology pipeline, particularly its lead programs targeting well-established drivers like SHP2 and FGFR2, yet the recent news exclusively highlights progress in a rare vascular disorder indication—raising questions about whether the company is shifting focus away from its core cancer franchises due to disappointing or stalled oncology data that were not disclosed in the update. The absence of any mention of oncology trial progress in the news release, combined with no recent earnings call to provide context, suggests potential evasion or lack of material progress in higher-value cancer indications, which could imply that the vascular data, while scientifically encouraging, may not be representative of the company's broader R&D productivity. Investors should scrutinize whether resources are being diverted from higher-potential but riskier oncology bets to lower-complexity rare disease projects as a means of generating near-term news flow.
While the vascular disorder trial showed tumor shrinkage and symptom improvement, the news release provided no clarity on key differentiators such as durability of response, comparative efficacy against existing off-label therapies, or safety profile in a chronically ill patient population—critical factors that determine whether this asset can achieve meaningful commercial traction or merely serve as a scientific curiosity. Rare vascular disorders often have limited patient populations (potentially fewer than a few thousand eligible patients globally), which constrains peak sales potential even under optimistic pricing assumptions, and may not justify the high R&D spend associated with Relay’s platform-dependent drug discovery model without clear paths to expansion into larger indications. Furthermore, the company’s reliance on its proprietary Dynamo platform introduces execution risk; if the vascular success is viewed as an isolated incident rather than a repeatable outcome, skepticism may grow regarding the platform’s ability to consistently deliver clinically differentiated candidates across therapeutic areas.